Most Read Articles
Rachel Soon, 6 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

Iron infusion better than iron pill for treating anaemia after GI bleeding

20 Jul 2019

Administering ferric carboxymaltose (FCM) infusion results in faster and more efficient normalization of haemoglobin (Hb) and iron status parameters, with a better tolerability profile, when compared with oral ferrous sulphate (FeSulf) in patients with anaemia secondary to acute gastrointestinal (GI) bleeding, as shown in a recent study.

The 42-day study randomized 61 adult patients with Hb <10 g/dL upon discharge (day 0) to receive FCM (n=29; 1,000 mg on day 0; 500 or 1,000 mg on day 7; per label) or FeSulf (n=32; 325 mg/12 hours for 6 weeks).

Complete response rate (Hb ≥12 g/dL in women and ≥13 g/dL in men) at day 42, the primary outcome measure, was higher in the FCM than in the FeSulf group (100 percent vs 61.3 percent; p<0.001). Of note, this difference was observed as early as day 21 (85.7 percent vs 45.2 percent; p=0.001).

Results for secondary outcomes were also more favourable with FCM. Significantly more FCM- vs FeSulf-treated patients achieved partial response (Hb increment ≥2 g/dL from baseline) at days 21 (100 percent vs 67.7 percent; p=0.001) and 42 (100 percent vs 74.2 percent; p=0.003), as well as normalization of transferrin saturation to 25 percent by the end of the study period (76.9 vs 24.1 percent; p<0.001).

None of the patients in the FCM group reported any adverse event in comparison with 10 patients in the FeSulf group (eg, constipation and abdominal pain).

According to researchers, the present data could provide clinical support for the inclusion of ferric carboxymaltose into treatment schemes and guidelines in the management of patients with anaemia following acute haemorrhage of GI origin.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 6 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.